Gilteritinib

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Treatment of FLT3-mutated acute myeloid leukemia (AML)

Link	Tested on	Notes	Publication date
The Host Cell ViroCheckpoint: Identification and Pharmacologic Targeting of Novel Mechanistic Determinants of Coronavirus-Mediated Hijacked Cell States Preprint	in silico	one of the top drugs and compounds identified by ViroTreat	May/17/2020
Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19 Preprint	Huh7 cells		May/27/2020
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate Preprint	Calu-3 human airway epithelial cells	higher IC50 value in Calu-3 cells than VERO E6 cells	May/12/2020

Link	Publication date
Bemcentinib and gilteritinib inhibit cell growth and impair the endo-lysosomal and autophagy systems in an AXL-independent manner.	Dec/15/2020
Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19	Apr/04/2022
Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy	Feb/21/2022
Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo	Mar/30/2021